Detection and diagnosis of smoking related cancers
View Patent ↗Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.
1. A method for identifying a subject at risk for the development of non-small cell lung cancer comprising:
(a) obtaining a test sample from a human subject;
(b) providing a 3p21 DNA probe selected from a CD39L3, PMGM, or GC20 gene probe;
(c) contacting the probe with the test sample;
(d) analyzing DNA from the test sample,
(e) detecting a loss of heterozygosity in the hybridization of the probe to the DNA, as compared to a centromeric DNA probe for chromosome 3; and
(f) identifying the subject at risk for the development of non-small cell lung cancer when loss of heterozygosity is detected.
2. The method of claim 1 , wherein the method further comprises providing a RPL14 gene probe.
3. The method of claim 1 , wherein the test sample comprises a surgical or biopsy specimen, a paraffin embedded tissue, a frozen tissue imprint, a sputum, esophageal brush, a fine needle aspiration, a buccal smear or a bronchial lavage.
4. The method of claim 1 , wherein the subject is a smoker.
5. The method of claim 1 , wherein the subject is a former smoker.
6. The method of claim 1 , wherein the subject is a non-smoker.
7. The method of claim 1 , wherein the test sample comes from the subject who has not previously been diagnosed with cancer.
8. The method of claim 1 , wherein the probe is labeled with fluorophores.
9. The method of claim 1 , wherein probe is labeled with digoxigenin.
10. The method of claim 1 , wherein size of the probe is between 1000 and 2000 base pairs.
11. The method in claim 1 , further comprising performing a spiral CT-scan.
12. The method of claim 1 , wherein the method is used to identify subjects who need an intensive follow-up protocol.
13. The method of claim 1 , wherein the probes are used to identify subjects who are suitable for novel investigational therapeutic approaches.
14. The method of claim 1 , wherein said centromeric probe is labeled with a fluorophore.
15. The method of claim 14 wherein said centromeric probe is labeled with spectrum orange.
16. The method of claim 1 , wherein said centromeric probe is a chromosome 3 stable marker.
17. The method of claim 16 , wherein said centromeric probe is Centromere 3 (CEP 3).
18. The method of claim 1 , wherein analyzing comprises using FISH.
19. A method for predicting the development of non-small cell carcinoma in a subject comprising:
(a) obtaining a lung test sample from a human subject;
(b) providing a 3p21 DNA probe selected from a CD39L3, PMGM, or GC20 gene probe;
(c) contacting the probe with the test sample;
(d) analyzing DNA from the test sample,
(e) detecting a loss of heterozygosity in the hybridization of the probe to the DNA, as compared to a centromeric DNA probe for chromosome 3; and
(f) predicting the development of non-small cell carcinoma in the subject.
20. The method of claim 19 , wherein the method further comprises providing a RPL14 gene probe.
21. The method of claim 1 , wherein the 3p21 DNA probe is a CD39L3gene probe.
22. The method of claim 1 , wherein the 3p21 DNA probe is a PMGM gene probe.
23. The method of claim 1 , wherein the 3p21 DNA probe is a GC20 gene probe.
24. The method of claim 19 , wherein the 3p21 DNA probe is a CD39L3gene probe.
25. The method of claim 19 , wherein the 3p21 DNA probe is a PMGM gene probe.
26. The method of claim 19 , wherein the 3p21 DNA probe comprises is a GC20 gene probe.